Otulfi is FDA-approved for subcutaneous and intravenous formulations to treat the same conditions as Stelara (ustekinumab), ...

Irritable bowel syndrome (IBS) can mimic some symptoms of inflammatory bowel disease (IBD). Learn how their causes, diagnosis ...

With the introduction of a subcutaneous formulation, ENTYVIO has expanded patient convenience and global accessibility. Continued growth is supported by rising IBD prevalence and ongoing ...

A person may experience swollen feet for several reasons, from hot weather or pregnancy to serious health conditions such as heart disease or a blood clot. Treatment depends on the underlying ...

Some research suggests a possible link between depression and vitamin D deficiency. However, it’s not clear whether increasing vitamin D intake could relieve depression symptoms. Vitamin D is an ...

Total expected savings from ustekinumab biosimilars estimated to be €526 million in Germany, the United Kingdom and Sweden over three years; annual saving per patient estimated to be €5,167, €709, and ...

No significant differences in the risk of myocardial infarction, ischemic stroke, or cardiovascular-related death were observed in patients with psoriasis or psoriatic arthritis initiating treatment ...

Biological medicines, including biosimilar medicines, play an important role in healthcare, opening up many possibilities for the treatment of disease and illness. 8 of the top 10 medicines prescribed ...

The concerns around the Stelara exclusivity appear overblown. China’s new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins for Matt Maley. Get the ...

They have also faced slow uptake as physicians and health systems struggle to adapt to the new treatment paradigm. Both Humira and Stelara work by tamping down the inflammatory response and share a ...

Johnson & Johnson also got a boost to Buy. Haider said concerns about losing patent protection on its blockbuster drug Stelara may be overstated. He pointed out that pharmaceutical valuations tend ...

The debuts of lower-cost biosimilars for AbbVie's rheumatoid arthritis drug Humira in 2023 and Janssen’s immunology medication Stelara this year, which cost about $7,000 and $10,000 a month ...